The antiplatelet activity of DC-015, a newly synthesized quinazoline derivative was determined in human platelet-rich plasma. From the binding studies, the Ki values of DC-015 for alpha 1-, alpha 2-adrenoceptors and 5-HT1, 5-HT2 receptors were about 0.21 (nM), 0.59 (microM), 0.16 (microM) and 0.38 (microM), respectivity. On the other hand, the Ki values of prazosin for alpha 1- and alpha 2-adrenoceptors were about 0.19 (nM) and 4.8 (microM), respectivity. Experimental results indicated that DC-015 dose-dependently inhibited noradrenaline (10 microM)-induced platelet aggregation in human platelet-rich plasma. At 20 microM, DC-015 would completely inhibit platelet aggregation induced by noradrenaline. A high concentration of prazosin (> 30 mM) caused sligh inhibition of aggregation. Furthermore, DC-015 (2 microM) significantly increased the cyclic AMP level in human platelet-rich plasma, whereas, prazosin significantly increased cyclic AMP level only at higher concentrations (100 microM). We can conclude that DC-015 inhibited noradrenaline-induced platelet aggregation mainly through binding to alpha 2-receptor on platelets, resulting in inhibiting platelet aggregation.